Published Date : Oct 2023
Category : Oncology
Delivery Timeline : 48 hrs
Buy NowOrder by POGet a quote
Login To Access

Fighting With Lymphoma for a Better Tomorrow

“Lymphoma: Exploring Innovations and Improving Quality of Life”

Lymphoma is one of the most common forms of cancer affecting people worldwide. It has become a major public health problem and changing the quality of life. World Cancer Research Fund International states that there are a total 18.1 million of cancer cases reported out of which 3.5% of cases are of Lymphoma.

Lymphoma is a wide term for cancer that develops in lymph system cells. Lymphoma develops when healthy B cells, T cells, or NK cells in the lymphatic system change and proliferate uncontrollably, potentially forming a tumor.

However, non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are two frequent malignant lymphoid disorders that are becoming a concern to public health. According to GLOBOCAN 2020 figures, the estimated global incidence and mortality from HL were 83,087 and 23,376 and for NHL it was 544,352 and 259,793.

The common symptoms of lymphoma are enlarged lymph nodes in the belly, groin, neck, or underarms spleen or liver enlargement, Weight reduction greater than 10% of total weight with no apparent cause, sweating and shivering, itchy skin, commonly known as pruritus. If the lymph nodes in the chest are impacted, it can cause shortness of breath, coughing, and chest pain.

However, the prevalence and incidence of lymphoma differ from region to region. The National Cancer Institute report states that in the US there are around 89,380 cases of Lymphoma reported in 2023. However, out of total lymphoma cases, 80,550 cases are of non-Hodgkin lymphoma and 8,830 cases are of Hodgkin lymphoma.

In addition to that, for Hodgkin Lymphoma, it has been reported by NCI that 900 deaths were reported in the US during 2023 of which 540 were males and 360 were females. The death rate has dropped by 4% every year as stated by NCI.  However, the projected global mortality rate from Hodgkin lymphoma in 2020 was 23,376.

Due to improvements in the treatment sector, the survival rate for HL is increasing. World Cancer Research Fund states that people with localized Hodgkin lymphoma had a 5-year relative survival rate of 93%. The 5-year relative survival rate is 95% if the cancer spreads regionally. The 5-year relative survival percentage for cancer that has spread to other areas of the body is 83%.

Moreover, children and adults are both affected by Lymphoma. It is most prevalent in two age groups. People in their early adult years, especially those in their 20s, constitute the first group. The second category consists of adults over 55. However, 39 is the typical diagnostic age. The disease is uncommon in children under the age of 5, but it is the most often diagnosed malignancy among teenagers between the ages of 15 and 19. At this age, the illness is accountable for 11% of all cancer cases as stated by NCI.

The common risk factors for Lymphoma include age, sex, viral infection, weak immune system, previous cancer history or treatment, autoimmune diseases, and other chemicals that have an impact on the genetic makeup of cells. All the above risk factors cause serious complications. In-depth research is required to treat the Lymphoma and reduce the risk of getting Lymphoma.

Numerous variables, including a high incidence rate and the lack of early diagnosis tools, have an impact on the lymphoma industry. The sector is growing tremendously due to other variables including the rise in medical disorders throughout the world and the challenges in figuring out the root causes of ailment development.

Currently, it is necessary to find lymphoma early. In the Lymphoma landscape, the emergence of therapeutic therapies that are less expensive and have fewer side effects is crucial. Market participants now have several chances to participate in this industry and increase their company's worth. 

Making educated decisions in the area of medical technology, therapies, and diagnostics is made easier here by DiseaseLandscape Insights since new technologies and ground-breaking developments change the environment and encourage more growth.

Lymphoma Diagnostic Analysis-

“Early Diagnosis Of Lymphoma: Saving the Lives”

The diagnosis of Lymphoma is based on the type of Lymphoma, signs and symptoms of patients, medical history of the patient, physical evaluation, age, and interpretation of previous test results. The following diagnostic techniques are performed to diagnose Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

  1. Biopsy

The biopsy is performed by removing a small portion of tissue and observing it under a microscope. Typically, tissues from swollen or affected lymph nodes in the neck, groin, or below an arm are removed to diagnose lymphoma. Biopsy is the only way to diagnose lymphoma accurately and identify the subtype of lymphoma.

  1. Imaging Tests

Imaging tests like computational tomography (CT), magnetic resonance imaging (MRI), ultrasound, chest X-ray, and positron emission tomography (PET) are used to capture the images of chest, abdomen, and pelvis. Imaging tests also help to detect whether cancer has spread to the lungs, lymph nodes, spleen, and liver. CT scan and MRI helps to measure the size of tumors and PET is useful to look at the structure of tumor and helps to measure the amount of energy tumor cell and normal cell use.

  1. Biomarker Testing

Biomarker testing is performed on tumor samples or bone marrow tissue to identify specific genes, proteins, and other unique biomarkers. Biomarker testing is also known as molecular or genetic testing which assists clinicians in choosing treatment options for particular patients.

Cytogenetics is a type of molecular test that detects changes in the number and structure of chromosomes unique to cancer. However, flow cytometry and immunohistopathy identify the protein attached to the surface of cancer cells. Also, molecular testing or gene sequencing helps to find out changes in base pairs of DNA in cancerous cells.

Diagnostic tests are typically performed in public laboratories that are built with the necessary equipment as well as highly experienced workers. The market for Lymphoma diagnostics is quite crowded, and many industry companies are contributing to this sector.

Using technology and extensive research, industry companies have the opportunity to develop revolutionary low-cost, accurate, and rapid biopsy procedures. Diagnostic procedure advancements and development increase the benchmark for significant stakeholders.

The below table highlights the industry players who are transforming the lymphoma diagnostic domain with their advanced strategies and their products are listed below.

Diagnostic Market Players


Roche Molecular System, Inc.

Cobas EZH2 Mutation Test

Foundation Medicine, Inc.

FoundationOne® Liquid CDx

PreXion, Inc.

PreXion 3D Excelsior CBCT Scanner

GE Healthcare

SIGNA™ Premier

Siemens Healthcare

Row CT Scanner

Shimadzu Corporation

EZy-Rad Pro


Lymphoma Treatment Analysis-

“Reviewing the Treatment Advancement to End the Lymphoma”

There are various treatment options available for lymphoma in the market. The treatment depends on the type of Lymphoma, the stage of cancer, the overall health of the patient, the history of patients, and previous results of tests. The following treatment techniques are used to manage lymphoma.

  1. Chemotherapy

Chemotherapy uses drugs to destroy the cancer cells. A chemotherapy regimen, often known as a treatment plan, usually consists of a defined number of cycles administered over a specific period of time. A patient may take one drug at a time or a variety of medications administered simultaneously. The chemotherapy utilized depends on the stage and kind of Lymphoma.

However, side effects of chemotherapy vary depending on the medicine and the amount utilized. They might include fatigue, transient blood count drops, increased infection risk, nausea and vomiting, hair loss, loss of appetite, rash, and diarrhea. These adverse effects are manageable while on medication.

  1. Radiation Therapy

Radiation therapy kills malignant cells by using high-energy rays. Involved site radiation therapy, intensity-modulated radiation therapy, and proton therapy are some of the types of radiation therapy used in lymphoma treatment.

However, the acute side effects of radiation treatment are determined by the location of the body being treated. Everyone who receives radiation therapy develops fatigue or low skin responses. Those who get neck radiation therapy may experience painful lips and/or throat. Radiation treatment to the mediastinum results in a cough, nausea, or swallowing discomfort.

  1. Targeted Therapy

Targeted therapy is a type of cancer treatment that targets specific genes, proteins, or the tissue environment that plays a role in cancer development and survival. This kind of therapy restricts cancer cell development and spread while protecting healthy and normal cells. Kinase inhibitors, immunomodulatory medicines, and nuclear export inhibitors are examples of targeted therapy used to treat Lymphoma.

  1. Immunotherapy

Immunotherapy enhances the immune system's ability to target cancer cells, enabling it to fight cancer naturally. Monoclonal antibodies, modified T cells, and checkpoint inhibitors are all examples of lymphoma therapy. Immunotherapy is a type of cancer treatment that involves anti-lymphoma techniques to enhance, target, or restore immune system function.

However, different forms of immunotherapy result in a variety of adverse effects. Skin rashes, flu-like symptoms, diarrhea, and weight fluctuations are all general side effects of immunotherapy. There is a need for the development of therapies with fewer side effects and low cost.

Industry players have various opportunities in the form of the Lymphoma treatment market. The market players focus on the production of diverse cost-effective therapy products, as well as the redevelopment of current medicines via the use of new technologies to enhance patient health while increasing the profit of the company.

Market research and consulting services of DiseaseLandscape Insights assist key players to stay upright in the treatment field of lymphoma. DLI provides comprehensive assistance with planning, carrying out, and analyzing clinical trials for the development of novel drugs.

The names of market competitors whose breakthroughs in treatment procedures and products are altering healthcare are mentioned below.

Treatment Market Player


GLS Pharma Ltd.


Biochem Pharmaceutical Industries Ltd.


Jubilant Cadista Pharmaceuticals Inc.


Pfizer Medical

Vincristine (Vincasar)

Janssen Biotech, Inc.

Ibrutinib (Imbruvica)

AstraZeneca Pharmaceuticals

Acalabrutinib (Calquence)

Eli Lilly and Company

Pirtobrutinib (Jaypirca)

Bayer HealthCare Pharmaceuticals

Copanlisib (Aliquopa)


Lenalidomide (Revlimid)

Epizyme Inc.

Tazemetostat (Tazverik)

AbbVie Inc.

Venetoclax (Venclexta)

BeiGene USA Inc.

Zanubrutinib (Brukinsa)

Karyopharm Therapeutics

Selinexor (Xpovio)


Rituximab (Rituxan)

AbbVie Inc.

Epcoritamab (Epkinly)


Glofitamab (Columvi)

Xencor, Inc.

Tafasitamab-cxix (Monjuvi)

Teva Pharmaceutical Industries Ltd.

Bendamustine (Treanda)


Pembrolizumab (Keytruda)

Bristol Myers Squibb

Nivolumab (Opdivo)


Regulatory Framework for Lymphoma–

“Understanding Regulatory Structure: Establishing Stable Business”

DiseaseLandscape Insights sorts the regulatory criteria from several nations for Lymphoma. DLI offers empirical findings regarding risk assessment, monitoring, and regulatory adherence. Organizations and market participants can prevent, manage, and react to flare-ups of lymphoma and protect the safety of affected people by exploring the DiseaseLandscape Insights services.

However, the FDA granted rapid approval to Mosunetuzumab-axgb (Lunsumio) on December 22, 2022, for adult patients with relapsed or refractory follicular lymphoma resulting from two or more lines of systemic treatment.

Moreover, Glofitamab-gxbm has received accelerated approval by the FDA for a subset of relapsed or refractory large B-cell lymphomas. The Food and Drug Administration gave glofitamab-gxbm a rapid approval on June 15, 2023.

Overall, regulatory rules have a considerable influence on the Lymphoma sector, and DLI offers an in-depth evaluation of several regional standards that are now in place, as well as prospective future changes in the Lymphoma illness market.

Competitive Analysis-

“Industry Competitors: Reviewing the Plan of Action of Market Players”

Several international industries are concentrating on manufacturing new products and enhancing the use of technology to improve current processes to increase their level of competition. Companies are also concentrating on ways to expand their product offerings, most commonly through collaborations, and regulatory approval for new drugs, medical research, and devices.

However, companies like BeiGene USA Inc. launched Zanubrutinib (Brukinsa) drug in the market for the treatment of Lymphoma in 2019. The development and marketing of such products has increased the awareness of disease and products in the public. Such inventions have increased the total revenue of BeiGene USA Inc. and also the collaborations of the company.

Furthermore, Genentech, Inc. has developed a drug called Glofitamab-gxbm for the treatment of B-cell Lymphomas. Manufacturing and marketing of such products is increasing the economy of the company. The global sales of products increased and the collaborations of Genentech, Inc. have enhanced. The company has set a standard for other competitors and existing industry players.

Market Trends-

“Understanding the Market Dynamics to Develop Better Business”

Research on cancers like lymphoma has become more specialized in terms of their molecular properties as a result of advances in gene sequencing and other tumor characterization techniques. As the outcome of mutations in certain genes and proteins, it is now feasible to identify distinct disease subpopulations in Lymphoma, leading to the development of new, more potent therapies.

However, Stand Up to Cancer awarded a $8 million grant to a leading team of scientists to develop medicines that employ a person's immune cells to detect and kill T-cell lymphoma, a category of rare blood and immune system tumors. Key players have tremendous scope in the immunotherapy industry of Lymphoma to establish a business and achieve great heights.

Moreover, innovations in CAR-T therapy including the entire spectrum of T-cell Lymphomas are now in trend. Market players have various opportunities in the development of CAR-T therapy for each type of Lymphoma with fewer side effects and low cost.

Two drugs that target the B-cell receptor signaling pathway have been authorized by the FDA. Calquence (acalabrutinib) has been approved for the treatment of relapsed mantle cell lymphoma and small lymphocytic lymphoma. Acalabrutinib, in conjunction with chemotherapy and rituximab, is being tested in persons with previously untreated diffuse large B-cell lymphoma in a current NCI research.

Industry players have a number of ways to develop combination therapy for the management of lymphoma. New drug discovery and development, research in targeted therapy, and invention of new treatment techniques for complete cure of Lymphoma are some of the areas where stakeholders enter and generate huge revenue.

Clinical Trial Data Assessment-

The government's increased emphasis on comparing the effectiveness of studies highlights the essential importance of clinical trials in the practice of evidence-based medicine and health care reform. One of the main aims of healthcare reform is realized by market participants thoroughly assessing medical therapy using clinical data.

The table below includes the study names of the ongoing clinical trials as well as the stages at which they are taking place.

Phase I

Phase II

Phase III

Phase IV

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies or Lymphomas.

An Open-Label, Multicenter, Single-Arm, Phase-2 Study of Single-Agent Mosunetuzumab (BTCT4465A, RO7030816) for the Treatment of Patients with Newly Diagnosed Follicular Lymphoma in Need of Systemic Therapy

Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Inhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant with Chemotherapy in Patients with Non-Hodgkin Lymphoma.

Vaccine Responses in Patients with B Cell Malignancies

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults with Relapsed or Refractory B-cell Lymphomas

A Phase 1/2, Open-label Study of Valemetostat in Combination with Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma

Enhancing Effect on Tumour Apoptosis with the Combined Use of Pentoxifylline Plus Chemotherapeutical Agents in Pediatrics and AYA Patients with Hodgkin´s Lymphoma

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Recombinant Fully Human Anti-CD39 Monoclonal Antibody JS019 in Patients with Advanced Solid Tumors or Lymphomas

A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination with Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients with CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)

Shortened vs Standard Chemotherapy Combined with Immunotherapy for the Initial Treatment of Patients with High Tumor Burden Follicular Lymphoma. A Randomized, Open Label, Phase III Study by Fondazione Italiana Linfomi

Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After Induction Therapy of Rituximab Combined with Bendamustine (BR) or Cyclophosphamide, Vincristine, Doxorubicin, Prednisone (RCHOP) or Lenalidomide (R2): a Multicenter Clinical Study

Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults with Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes

Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study

A Randomised Phase III Trial with a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients with Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Clinical Study on the Effectiveness and Safety of PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells for Lymphoma and Multiple Myeloma

Biological: IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection

A Phase II Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma

Efficacy of Consolidative Involved-site Radiotherapy Following Effective Chemotherapy for Patients with Limited-stage Follicular Lymphoma: Wuhan University Cancer Center -NHL01 Trial

Efficacy and Safety of Plerixafor in Patients with Poorly Mobilized Lymphoma



DiseaseLandscape Insights (DLI) identifies the importance of understanding the disease dynamics, especially in the Lymphoma disease sector. DLI's comprehensive services are intended to help the healthcare sector, its professionals, researchers, and other industry participants improve patient outcomes while strengthening and expanding their businesses.

Our extensive research on the Lymphoma disease market and valuable service provide knowledge about recent developments in diagnostic tools, novel drug launching, advancements in therapies, and emerging techniques in the Lymphoma domain. This enables healthcare professionals to make informed decisions, devise targeted strategies, and deliver personalized care to patients.

This allows market leaders to do concentrated R&D, learn about contract manufacturing organizations, discover raw material suppliers, and assure legal compliance for the business. All in all, DLI assists market players to stay strong and helps to grow the continuous Lymphoma field.

Vishal SawantBusiness Development

How we can help?

  • 1-888-853-7040 - U.S. (TOLL FREE)
  • +44-1173181773 - U.K. OFFICE
  • +91-7447409162 - INDIA OFFICE
1Chat With UsBook AppointmentBook 15 min Free Analyst Call
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us
  • FAQ
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1, Solitaire Business Hub, Viman Nagar, Pune, Maharashtra, 411014
1-888-853-7040 - U.S. (TOLL FREE)+44-1173181773 - U.K. OFFICE+91-7447409162 - INDIA OFFICE
© Copyright 2024-25 Disease Landscape Insights LLP. All Rights Reserved | Designed by Disease Landscape